Other languages Satellos Bioscience Inc.

Equities

MSCL

CA80401L3083

Delayed Toronto S.E. Other stock markets 11:15:06 2024-04-29 am EDT			5-day change	1st Jan Change
0.48 ^CAD	0.00%		0.00%	+11.63%

Mar. 27	Satellos Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 27	Satellos Bioscience Announces FY 2023 Results	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Satellos Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27
Satellos Bioscience Announces FY 2023 Results	Mar. 27
Satellos Presented "Positive" Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference	Mar. 04
Satellos Presents Positive Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference	Mar. 04
Satellos Bioscience Inc. Announces Promising Preliminary Data in Facioscapulohumeral Muscular Dystrophy	Feb. 13
Satellos Bioscience Inc. Announces Executive Changes	Jan. 23
Satellos Receives Conditional Approval To Graduate To The Toronto Stock Exchange	Jan. 16
Satellos Bioscience Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 22
Satellos Bioscience Announces 2023 Q3 Financial Results and Operational Highlights	Nov. 22
Satellos Bioscience Inc. Announces Executive Changes	Nov. 22
Satellos Bioscience Inc. Discloses Drug Target and Provides Development Update on Duchenne Muscular Dystrophy Program	Nov. 14
Satellos Bioscience Names New CFO; Up 3.8%	23-09-05
Satellos Bioscience Inc. Announces Appointment of Warren Whitehead as Head of Corporate Strategy	23-09-05
Satellos Bioscience Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-27
Satellos Bioscience Inc. Announces Appointment of Alan K. Jacobs as Chief Medical Officer	23-06-07
Satellos Bioscience Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-30
Satellos Bioscience Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29
Satellos Bioscience Inc. Auditor Raises 'Going Concern' Doubt	23-03-29
Satellos Bioscience Inc. Announces Additional Results from Further Preclinical Studies Using Its Lead Drug Candidate SAT-3153	23-03-10
Satellos Bioscience Inc Announces Results from Multiple Preclinical Studies in A Disease Model of Duchenne Muscular Dystrophy	23-02-06

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Satellos Bioscience Inc.

Equities

MSCL

CA80401L3083

Other languages

Filters